Page last updated: 2024-11-12
cj-023,423
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
grapiprant: a potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties; cyclooxygenase inhibitors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11677589 |
| CHEMBL ID | 3039498 |
| SCHEMBL ID | 120428 |
| MeSH ID | M0513562 |
Synonyms (61)
| Synonym |
|---|
| 415903-37-6 |
| cj-023 |
| cj-023423 |
| cj-023,423 |
| j9f5zph7nb , |
| mr-10a7 |
| mr10a7 |
| rq-00000007 |
| unii-j9f5zph7nb |
| grapiprant [usan:inn] |
| 1-(2-(4-(2-ethyl-4,6-dimethylimidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)-3-(4-methylphenyl)sulfonylurea |
| benzenesulfonamide, n-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)amino)carbonyl)-4-methyl- |
| rq-7 |
| aat-007 |
| grapiprant |
| cj 023423 |
| S6694 |
| CHEMBL3039498 |
| 1-[2-[4-(2-ethyl-4,6-dimethylimidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea |
| gtpl5858 |
| grapiprant [who-dd] |
| grapiprant [inn] |
| grapiprant [usan] |
| 2-ethyl-4,6-dimethyl-1-(4-(2-(((((4-methylphenyl)sulfonyl)amino)carbonyl)amino)ethyl)phenyl)-1h-imidazo(4,5-c)pyridine |
| grapiprant [green book] |
| grapiprant [mi] |
| n-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)amino)carbonyl)-4-methyl-benzenesulfonamide |
| n-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)ethyl)amino)carbonyl)-4-methylbenzenesulfonamide |
| HZVLFTCYCLXTGV-UHFFFAOYSA-N |
| n-[([2-[4-(2-ethyl-4,6-dimethyl-1h-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino)carbonyl]-4-methylbenzenesulfonamide |
| SCHEMBL120428 |
| D10638 |
| grapiprant (usan/inn) |
| bdbm50107283 |
| HY-16781 |
| CS-5392 |
| DTXSID60194419 |
| AKOS030526811 |
| n-((4-(2-ethyl-4,6-dimethyl-1h-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide |
| cj-023423; rq-00000007; aat-007 |
| DB12836 |
| BCP20570 |
| grapiprant; rq-00000007; aat-007; cj-023423 |
| EX-A2544 |
| Q27077852 |
| SB18902 |
| cj-023423;rq-00000007;aat-007 |
| D83673 |
| A900379 |
| B0084-470919 |
| grapiprant (cj-023423) |
| aat-007cj-023423 |
| AS-77380 |
| n-(((2-(4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl) phenyl)ethyl)amino)carbonyl)-4-methylbenzenesulfonamide |
| rq-07 |
| galliprant |
| n-((2,4-(2-ethyl-4,6-dimethyl-1h-imidazo(4,5-c)pyridin-1-yl)phenylethylamino)carbonyl)-4-methyl-benzenesulfonamide |
| grapiprantum |
| cj023,423 |
| AC-36123 |
| n-(4-(2-ethyl-4,6-dimethyl-1h-imidazo[4,5-c]pyridin-1-yl)phenethylcarbamoyl)-4-methylbenzenesulfonamide |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Grapiprant was well tolerated, and no adverse effects were detected at doses ≤ 15 mg/kg." | ( Safety and toxicokinetic profiles associated with daily oral administration of grapiprant, a selective antagonist of the prostaglandin E2 EP4 receptor, to cats. Rausch-Derra, LC; Rhodes, L, 2016) | 0.43 |
Pharmacokinetics
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " From this class, a potent and highly bioavailable compound (6) has been selected for potential clinical studies." | ( Discovery and characterization of a potent and selective EP4 receptor antagonist. Chandrasekhar, S; Fisher, MJ; Harvey, A; Kuklish, SL; Schiffler, MA; Wang, XS; Warshawsky, AM; York, JS; Yu, XP, 2015) | 0.42 |
| "To assess the effect of food intake on the pharmacokinetics of grapiprant administered orally at 2 mg/kg, and to estimate its oral bioavailability in dogs." | ( Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E Barsotti, G; Gazzano, A; Giorgi, M; Lisowski, A; Owen, H; Łebkowska-Wieruszewska, B, 2017) | 0.46 |
| " The estimated bioavailability in fasted and fed dogs was 111." | ( Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E Barsotti, G; Gazzano, A; Giorgi, M; Lisowski, A; Owen, H; Łebkowska-Wieruszewska, B, 2017) | 0.46 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Structural modifications on lead compound 4a were explored with the aim of improving potency, physicochemical properties, and animal PK predictive of QD (once a day) dosing regimen in human." | ( Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Nakao, K; Nukui, S; Okumura, Y; Yamagishi, T, 2017) | 0.46 |
| " Simulations support a dosing frequency of 12-hour intervals with food reaching minimum effective concentrations established for canines, although it is unknown whether these plasma concentrations are therapeutic for birds." | ( Absorption of grapiprant in red-tailed hawks (Buteo jamaicensis) is decreased when administered with food. Drazenovich, TL; Hawkins, MG; Knych, HK; Paul-Murphy, JR; Rodriguez, P, 2022) | 0.72 |
| " Pain and inflammation were assessed by masked investigators via mechanical nociceptive threshold testing and the short form of the Glasgow Composite Pain Scale before drug administration and at multiple time points for 72 hours following dosing and surgery." | ( Preliminary evaluation of the effects of grapiprant compared with carprofen on acute pain and inflammation following ovariohysterectomy in dogs. Barnes, DN; Enomoto, H; Long, SM; Messenger, KM; Southern, BL, 2022) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (10)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Thromboxane A2 receptor | Homo sapiens (human) | Ki | 5.0000 | 0.0006 | 1.2407 | 3.8040 | AID1430132 |
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | Ki | 5.0000 | 0.0091 | 0.6635 | 1.5849 | AID1430141 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | IC50 (µMol) | 0.1810 | 0.0004 | 0.9585 | 8.0390 | AID1238243; AID1238244; AID1266062; AID1294271 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | Ki | 0.3033 | 0.0001 | 0.4744 | 3.1623 | AID1238243; AID1266061; AID1430136 |
| Prostaglandin F2-alpha receptor | Homo sapiens (human) | Ki | 5.0000 | 0.0310 | 3.3803 | 9.9910 | AID1430146 |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | Ki | 0.0200 | 0.0200 | 0.0200 | 0.0200 | AID1430130 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | Ki | 5.0000 | 0.0003 | 1.7081 | 6.8000 | AID1430143 |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | Ki | 5.0000 | 0.0010 | 0.5448 | 3.0000 | AID1430142 |
| Prostacyclin receptor | Homo sapiens (human) | Ki | 5.0000 | 0.0032 | 0.4958 | 6.6280 | AID1430131 |
| Prostaglandin E2 receptor EP4 subtype | Canis lupus familiaris (dog) | Ki | 0.0240 | 0.0240 | 0.0240 | 0.0240 | AID1430128 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin E2 receptor EP4 subtype | Mus musculus (house mouse) | Kd | 0.0078 | 0.0078 | 0.0078 | 0.0078 | AID1430127 |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | Kd | 0.0048 | 0.0018 | 0.0033 | 0.0048 | AID1430133 |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | Kd | 0.0065 | 0.0065 | 0.0065 | 0.0065 | AID1430129 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (54)
Molecular Functions (7)
Ceullar Components (8)
Bioassays (29)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1430136 | Displacement of [3H]PGE from human EP4 receptor expressed in HEK293 cell membranes | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1238243 | Displacement of [3H]-PGE2 from recombinant human EP4 receptor expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting analysis | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Discovery and characterization of a potent and selective EP4 receptor antagonist. |
| AID1266061 | Antagonist activity at human EP4 receptor | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists. |
| AID1266066 | Drug metabolism in human hepatic microsomes | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists. |
| AID1430127 | Antagonist activity at mouse recombinant EP4 receptor assessed as inhibition of PGE2-induced cAMP level by cell based assay | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1266067 | Aqueous solubility of the compound at pH 6 | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists. |
| AID1430130 | Antagonist activity at rat recombinant EP4 receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430132 | Antagonist activity at human platelet TP receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1272653 | Antagonist activity at EP4 receptor in LPS-stimulated human whole blood assessed as inhibition of PGE2-induced TNF-alpha release pretreated for 30 mins followed by addition of PGE2 measured after 20 to 24 hrs by immunoassay | 2016 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3 | Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile. |
| AID1266063 | Antagonist activity at EP4 receptor in human whole blood assessed as reversal of inhibition of PGE2 mediated LPS-induced TNF alpha production pretreated for 30 mins using 3,3',5,5' tetramethylbiphenyl-4,4'-diamine substrate measured after 20 to 24 hrs by | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists. |
| AID1238245 | Antagonist activity at EP4 receptor in LPS-stimulated human whole blood assessed as inhibition of PGE2-induced TNF-alpha reduction preincubated for 30 mins followed by PGE2 addition measured after 24 hrs by ELISA | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Discovery and characterization of a potent and selective EP4 receptor antagonist. |
| AID1430143 | Antagonist activity at human EP3 receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430144 | Analgesic activity in po dosed rat assessed as inhibition of carrageenan-induced mechanical hyperalgesia measured at 1 hr post dose | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430182 | Analgesic activity in po dosed rat model of chronic inflammatory pain assessed as inhibition of CFA-induced weight bearing deficit | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1294238 | Aqueous solubility of compound at pH 6 at 2 mM after 20 hrs by HPLC | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. |
| AID1430131 | Antagonist activity at human IP receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430142 | Antagonist activity at human EP2 receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430128 | Antagonist activity at dog recombinant EP4 receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430146 | Antagonist activity at human FP receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1238244 | Antagonist activity at recombinant human EP4 receptor expressed in HEK293 cells assessed as inhibition of PGE2-stimulated cAMP accumulation by scintillation proximity assay in presence of [125I]-cAMP | 2015 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16 | Discovery and characterization of a potent and selective EP4 receptor antagonist. |
| AID1266062 | Antagonist activity at human EP4 receptor in HEK293 cells assessed as inhibition of PGE2-induced cAMP accumulation | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists. |
| AID1430133 | Antagonist activity at human EP4 receptor expressed in HEK293 cells assessed as inhibition of PGE2-induced cAMP level by HTS assay | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430145 | Antagonist activity at human DP receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1430141 | Antagonist activity at human EP1 receptor | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1294270 | Antagonist activity against EP4 in human whole blood assessed as reversal of PGE2-mediated suppression of LPS-induced TNF-alpha production preincubated for 30 mins followed by LPS stimulation measured after 20 to 24 hrs by enzyme immunoassay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. |
| AID1430129 | Antagonist activity at rat recombinant EP4 receptor assessed as inhibition of PGE2-induced cAMP level by cell based assay | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5 | Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. |
| AID1266065 | Drug metabolism in rat hepatic microsomes | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists. |
| AID1294271 | Antagonist activity against human EP4 expressed in HEK293 cells assessed as inhibition of PGE2-stimulated production of cAMP incubated for 20 mins by HTRF assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9 | Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists. |
| AID1346427 | Human EP4 receptor (Prostanoid receptors) | 2007 | The Journal of pharmacology and experimental therapeutics, Aug, Volume: 322, Issue:2 | CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (31)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (9.68) | 29.6817 |
| 2010's | 19 (61.29) | 24.3611 |
| 2020's | 9 (29.03) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.95
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.95) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (29.03%) | 5.53% |
| Reviews | 1 (3.23%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (67.74%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||